Monitor Resmed's upcoming quarterly reports for any contribution from Noctrix's Nidra therapy and management commentary on RLS market penetration. The acquisition strengthens Resmed's sleep health offering beyond sleep apnea, but financial impact is likely modest in the near term.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 2 $182.75entry
- T+1 · 6mo ago +1.71%α +2.43% · $185.87
- T+5 · 5mo ago +7.77%α +10.73% · $196.94
- T+20 · 5mo ago +10.04%α +11.86% · $201.10
- T+60 · 3mo ago +28.97%α +28.11% · $235.69
Price Chart
How similar events traded
Executive Summary
Resmed completed its acquisition of Noctrix Health, adding an FDA-cleared non-pharmacologic treatment for Restless Legs Syndrome (RLS) to its sleep health portfolio. The deal size was not disclosed, but the acquisition aligns with Resmed's 2030 strategy and expands its clinical sleep health offering beyond sleep apnea into RLS, the third most prevalent sleep disorder.
Key Facts
- Resmed completed acquisition of Noctrix Health on June 1, 2026.
- Noctrix's Nidra TOMAC Therapy is an FDA De Novo classified non-invasive treatment for moderate-to-severe RLS.
- The therapy is included in AASM clinical practice guidelines and supported by 10 peer-reviewed publications.
- Noctrix becomes a wholly owned subsidiary of Resmed.
- Financial terms of the acquisition were not disclosed.
Financial Impact
Not disclosed; strategic acquisition expected to expand portfolio into adjacent RLS market.
Risk Factors
- Integration and commercial execution of Noctrix's therapy into Resmed's portfolio.
- RLS treatment market adoption and reimbursement uncertainties.
- Potential for lower-than-expected revenue contribution from the newly acquired asset.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3304704 |
Track record
19 reports on RMD
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +10.92% at T+20 after the May 19, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $234.11 Now $238.19 +1.74% settles Dec 9
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $229.94 Now $238.19 +3.59% settles Nov 30
- Oct 16, 20264w ago Institutional Cluster Bearish 4/10 Entry $238.88 to $238.19 Now $238.19 +0.29% ▲ +0.29% −3.17% vs SPY
- Oct 7, 20265w ago 144 Neutral 3/10 Entry $226.73 to $240.51 Now $238.19 +5.05% ▲ +6.08% +11.37% vs SPY
- Oct 1, 20266w ago DEFA14A Neutral 2/10 Entry $218.89 to $229.94 Now $238.19 +8.82% ▲ +5.05% +6.86% vs SPY
- Oct 1, 20266w ago DEF 14A Neutral 4/10 Entry $218.89 to $252.83 Now $238.19 +8.82% ▲ +15.51% +17.31% vs SPY
- Oct 1, 20266w ago Press Release Neutral 1/10 Entry $218.89 Now $238.19 +8.82% No price data
- Sep 10, 20269w ago Insider Cluster Neutral 4/10 Entry $219.58 to $226.73 Now $238.19 +8.48% ▲ +3.26% +1.13% vs SPY
- Aug 11, 202613w ago Insider Cluster Neutral 2/10 Entry $224.84 to $219.95 Now $238.19 +5.94% ▼ −2.17% −1.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers